This promotional meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.

​

UK | January 2025 | FA-11346740

​​

​Fabhalta®▼ is indicated as monotherapy in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who have haemaolytic anaemia

​​

Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.

​

By clicking the below link (to MHRA Yellow Card) you will leave this Novartis-associated website. This link will take you to a website to which our privacy policy does not apply.

You are solely responsible for your interactions with that website.

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report

or alternatively email medinfo.uk@novartis.com or call 01276 698370